Literature DB >> 29879414

Chronic cerebral hypoperfusion accelerates Alzheimer's disease pathology with the change of mitochondrial fission and fusion proteins expression in a novel mouse model.

Tian Feng1, Toru Yamashita1, Yun Zhai2, Jingwei Shang1, Yumiko Nakano1, Ryuta Morihara1, Yusuke Fukui1, Nozomi Hishikawa1, Yasuyuki Ohta1, Koji Abe3.   

Abstract

Mitochondrial dynamically undergo massive fusion and fission events to continuously maintain their function in cells. Although an impaired balance of mitochondrial fission and fusion was reported in in-vitro and in-vivo Alzheimer's disease (AD) model, changes of mitochondrial fission and fusion proteins have not been reported in AD with chronic cerebral hypoperfusion (HP) as an etiological factor related to the development of elder AD. To clarify the impacts of HP on mitochondrial fission and fusion, related oxidative stress in the pathogenesis of AD, and protective effect of galantamine, the novel AD with HP mouse model (APP23 + HP) was applied in this project. Compared with APP23 mice, APP23 + HP mice greatly enhanced the number of Aβ oligomer-positive/phosphorylated tau (pTau) cells, the expression of mitochondrial fission proteins (Drp1 and Fis1), and decreased the expression of mitochondrial fusion proteins (Opa1 and Mfn1) in the cerebral cortex (CTX) and thalamus (TH) at 12 month (M) of age. Moreover, the expression of peroxidation products (4-HNE and 8-OHdG) showed a significant increase in CTX and TH of APP23 + HP mice at 12 M. However, above neuropathological characteristics were retrieved by galantamine (Gal) treatment, detected through immunohistochemical analyses. The present study demonstrates that cerebral HP shifted the balance in mitochondrial morphology from fusion to fission with increasing Aβ oligomer/pTau accumulations in APP23 mice, and such neuropathologic processes were strongly attenuated by Gal treatment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Aβ oligomer/pTau; Chronic cerebral hypoperfusion; Drp1/Fis1; Galantamine; Opa1/Mfn1; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29879414     DOI: 10.1016/j.brainres.2018.06.003

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Oxygen Sensing and Signaling in Alzheimer's Disease: A Breathtaking Story!

Authors:  Sónia C Correia; Paula I Moreira
Journal:  Cell Mol Neurobiol       Date:  2021-09-12       Impact factor: 5.046

2.  Association of Low Systolic Blood Pressure with Postmortem Amyloid-β and Tau.

Authors:  Shahram Oveisgharan; Ana W Capuano; Alifiya Kapasi; Aron S Buchman; Julie A Schneider; David A Bennett; Zoe Arvanitakis
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.160

3.  Resveratrol Activates Autophagy via the AKT/mTOR Signaling Pathway to Improve Cognitive Dysfunction in Rats With Chronic Cerebral Hypoperfusion.

Authors:  Nan Wang; Jinting He; Chengliang Pan; Jiaoqi Wang; Ming Ma; Xinxiu Shi; Zhongxin Xu
Journal:  Front Neurosci       Date:  2019-08-20       Impact factor: 4.677

4.  Tripchlorolide May Improve Spatial Cognition Dysfunction and Synaptic Plasticity after Chronic Cerebral Hypoperfusion.

Authors:  Zhao-Hui Yao; Xiao-Li Yao; Shao-Feng Zhang; Ji-Chang Hu; Yong Zhang
Journal:  Neural Plast       Date:  2019-02-24       Impact factor: 3.599

5.  Effect of circular RNA, mmu_circ_0000296, on neuronal apoptosis in chronic cerebral ischaemia via the miR-194-5p/Runx3/Sirt1 axis.

Authors:  Keyu Huang; Chunqing Yang; Jian Zheng; Xiaobai Liu; Jie Liu; Dongfang Che; Yixue Xue; Ping An; Di Wang; Xuelei Ruan; Bo Yu
Journal:  Cell Death Discov       Date:  2021-05-29

Review 6.  Prevention of Cognitive Decline in Alzheimer's Disease by Novel Antioxidative Supplements.

Authors:  Koh Tadokoro; Yasuyuki Ohta; Haruhiko Inufusa; Alan Foo Nyuk Loon; Koji Abe
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.